Key clinical point: Patients over the age of 80 years received similar benefits as younger patients from MM treatment.
Major finding: There was no statistically significant difference in treatment benefit based on age cohort (P = .610).
Study details: A database study of 2,155 patients diagnosed with MM at age 80 years or older, compared with 2,933 similar patients diagnosed at ages 70-79 years.
Disclosures: The study was funded by the National Cancer Institute. One author reported research funding from Janssen. The other authors had no relevant conflicts of interest.
Fiala MA et al. J Geriatric Oncol. 2020 Mar 10. doi.org/10.1016/j.jgo.2020.03.005.